While no medication directly targeting MYC has been tested in humans, APTO‐253, which partly reduces MYC expression, is currently undergoing phase I clinical trials in patients with relapsed/refractory acute myeloid leukaemia or myelodysplastic syndrome.7 It's worth noting that OmoMYC, being a peptide/small protein, may be susceptible to in vivo degradation. Here, MYC is linked to acute myeloid leukemia.